International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationPredictive Factors and Management of Rectal Bleeding Side Effects Following Prostate Cancer Brachytherapy
Introduction
Since its introduction to the clinic, low-dose-rate brachytherapy (BT) has been adopted as both a popular and efficacious treatment strategy for the management of localized prostate cancer (1). As the intraoperative placement of BT seeds has been refined, delivered radiation doses have increased, thus maximizing the therapeutic potential of BT (2). However, the escalation of local radiation doses has the potential to lead to chronic toxicities, especially within the context of combined modality therapies (CMT) that use supplemental external beam radiation therapy. One such toxicity, radiation proctitis, is due to the proximity of the posterior margin of the prostate to the anterior rectal wall and the inability to completely eliminate doses to this structure. Radiation proctitis has diverse clinical presentations typically including diarrhea, abdominal pain, constipation, and rectal bleeding (3).
In past work from our and other medical centers we have shown that the incidence of grade ≥2 proctitis can be limited by restricting the rectal volume receiving 100% of the prescription dose (RV100) to <1.3 mL 4, 5. Likewise, several groups have reported on the incidence of grade ≥2 proctitis following BT or CMT regimens, with incidence ranging from 1% to >9%, with much of the variability observed attributable to differences in treatment type and/or follow-up time (6). Yet, despite the widespread documentation of proctitis following the treatment of prostate cancer, few studies have reported on either grade ≥2 proctitis rates across multiple CMTs or the treatment of refractory rectal toxicities. In the present study, we therefore report a large (n=2572), retrospective analysis on the relationship between the nature, treatment, and predisposing factors contributing to the 10-year incidence of rectal morbidities following the treatment of localized prostate cancer using BT regimens.
Section snippets
Methods and Materials
All patients were treated for localized prostate cancer with low-dose-rate BT at Mount Sinai Hospital between October 1990 and April 2007. A total of 2752 patients were seen during this time frame with a median 5.86 years (minimum 1.0 years; maximum 19.19 years) follow-up time. The clinical characteristics of these patients are summarized in Table 1.
Upon evaluation of each patient's clinical history, tumor Gleason score, serum prostate-specific antigen (PSA), and T stage, patients were assigned
Results
The overall incidence of rectal morbidities following prostate cancer treatment is summarized in Table 3. The actuarial risk of developing grade 1 rectal bleeding was 20.57% (566 patients), whereas grade ≥2 bleeding/radiation proctitis was restricted to only 6.36% (175 patients) of the sample cohort (Fig. 1a). More severe treatment-related toxicities such as fistula formation or rectal ulceration were exceedingly rare, comprising only 9 (0.33%) cases. Moreover, most rectal morbidities were
Discussion
In this study, we have analyzed the incidence and factors predisposing to rectal toxicities following treatment of localized prostate cancer. We have shown that BT, either alone or combined with EBRT or ADT, is very well tolerated with actuarial risks of only 6.3% or 20.1% of patients developing primarily self-limiting grade ≥2 proctitis or grade 1 rectal bleeding, respectively. More severe rectal toxicities such as fistula (0.11%) or ulcer (0.22%) formation were especially rare and are in line
Acknowledgments
We thank Bruce Wunder and John Caligy for their help in maintaining our patient database and for assistance in statistical analysis.
References (30)
- et al.
Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis
Int J Radiat Oncol Biol Phys
(2001) - et al.
Probability of late rectal morbidity in 125I prostate brachytherapy
Int J Radiat Oncol Biol Phys
(2003) - et al.
Functional outcomes and complications following radiation therapy for prostate cancer: A critical analysis of the literature
Eur Urol
(2012) - et al.
A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation
Int J Radiat Oncol Biol Phys
(1995) - et al.
Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results
Int J Radiat Oncol Biol Phys
(2006) - et al.
Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation
Int J Radiat Oncol Biol Phys
(2002) - et al.
Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer
Int J Radiat Oncol Biol Phys
(2000) - et al.
Rectal fistulas after prostate brachytherapy
Int J Radiat Oncol Biol Phys
(2005) - et al.
Prospective evaluation of formalin therapy for radiation proctitis
Am J Surg
(1999) - et al.
Influence of hormonal therapy on late rectal function after permanent prostate brachytherapy with or without supplemental external beam radiotherapy
Int J Radiat Oncol Biol Phys
(2004)
Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: The standard of care?
Lancet Oncol
Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer
Int J Radiat Oncol
Combined intensity-modulated radiation therapy vs. three-dimensional highly conformal radiotherapy after (125)I prostate permanent seed brachytherapy: a comparative treatment planning study
Brachytherapy
Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer
Int J Radiat Oncol Biol Phys
Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: The relationship between dose-volume histogram parameters and the occurrence rate
Int J Radiat Oncol Biol Phys
Cited by (0)
Conflict of interest: R.G.S. has received payments for speaking on behalf of the following companies: C.R. Bard, Inc, and Varian Medical Systems and N.N.S. has received payments for speaking on behalf of the following companies: Amgen Inc, Centocor Ortho Biotech Inc, and Ferring Pharmaceuticals. These relationships do not interfere with or influence the scientific goals or mission of this publication and these entities had no input into the current study.